A global pandemic has left life sciences companies with giant targets on their backs for cyberattacks.
U.S. drugmaker Pfizer and the company’s German partner BioNTech said documents related to development of their Covid-19 vaccine were “unlawfully accessed” in a cyberattack on Europe’s medicines regulator.
Data analytics group GlobalData released a report that showed the global health care sector has been subjected to an array of cyberattacks as the industry deals with the COVID-19 pandemic.
Merck announced that the company pulled its application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer from the European Medicines Agency.
Merck & Co. reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda, but total revenue fell in third-quarter 2017 from disruptions due to the NotPetya cyber attack and loss of market share for many of the company’s older drugs.
Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co.’s loss from a cyber attack in June 2017, according to a forecast by Verisk Analytics Inc.’s Property Claim Services (PCS) unit.
Federal lawmakers are concerned that a recent cyberattack on pharma giant Merck & Co. could lead to numerous problems. including a drug shortage.
The international cyber attack Merck & Co. suffered in June halted some of the company’s manufacturing and other operations and cut its profit forecast for 2017.
